GNC-039 / Biokin Pharma - LARVOL DELTA

A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Active, not recruiting ➔ Recruiting | N=43 ➔ 60 | Trial completion date: Dec 2025 ➔ Dec 2026

Enrollment change • Enrollment open • Trial completion date • Brain Cancer • Glioma • Oncology • Solid Tumor

A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=43 | Active, not recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting ➔ Active, not recruiting | N=147 ➔ 43

Enrollment change • Enrollment closed • Brain Cancer • Glioma • Oncology • Solid Tumor

A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=147 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Jun 2025 ➔ Dec 2025 | Trial primary completion date: Jun 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Brain Cancer • Glioma • Oncology • Solid Tumor

A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=147 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Oct 2024 ➔ Jun 2025 | Trial primary completion date: Oct 2024 ➔ Jun 2025

Metastases • Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor

A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=147 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Jun 2024 ➔ Oct 2024 | Trial primary completion date: Jun 2024 ➔ Oct 2024

Metastases • Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor

A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=147 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Dec 2023 ➔ Jun 2024 | Trial primary completion date: Dec 2023 ➔ Jun 2024

Metastases • Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor

A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=147 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Metastases • Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor

Tetra-specific antibody GNC-039: guidance and navigation control (GNC) molecule development for treatment of EGFRvIII+ malignancies (AACR 2023) - "Groups received either GNC-039 (n=5), GNC-039 with engrafted PBMC (n=5), Temozolomide(n=5), or Vehicle (n=5). However, beyond this timepoint, the level of GNC-039 in the brain region was significantly increased due to the engrafted PBMC.Collectively this data indicates the functionality of GNC-039 as a multi-specific T cell engager with the potential to target EGFRvIII+ cancer cell cytolysis in primary brain disease. The clinical phase I-b study of GNC-039 is under way and the available data exhibit strong signals of efficacy with acceptable tolerability."

IO biomarker • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor • PD-L1

SystImmune to Present Data from Seven Preclinical Programs at the American Association of Cancer Research (AACR) Annual Meeting 2023 (PRNewswire) - "SystImmune...has announced that it will present data from seven preclinical programs in poster presentations at the American Association of Cancer Research (AACR) meeting....SystImmune will present its findings in several poster sessions at the AACR meeting, including 'Antibody Technologies', 'Therapeutic Antibodies, Including Engineered Antibodies', and 'Growth Factor Receptors as Therapeutic Targets'."

Preclinical • Oncology • Solid Tumor

A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=147 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Apr 2023 ➔ Aug 2023 | Trial primary completion date: Apr 2023 ➔ Aug 2023

Metastases • Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor

A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors (clinicaltrials.gov) - P1; N=147; Recruiting; Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.; Active, not recruiting ➔ Recruiting

Enrollment open • Brain Cancer • Glioma • Oncology • Solid Tumor

A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors (clinicaltrials.gov) - P1; N=147; Active, not recruiting; Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.; Not yet recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Brain Cancer • Glioma • Oncology • Solid Tumor

A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors (clinicaltrials.gov) - P1; N=147; Not yet recruiting; Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Clinical • New P1 trial • Alzheimer's Disease • Brain Cancer • Glioma • Oncology • Rheumatoid Arthritis • Solid Tumor